StreetAlpha.app
Home › Stocks › NAMS

NewAmsterdam Pharma Co N.V. (NAMS)

Healthcare
$18.41
▼ −5.64%
LAST CLOSE · NOV 20

NewAmsterdam Pharma develops obicetrapib, an oral pill for lowering LDL cholesterol in patients with cardiovascular disease or high cholesterol. It last closed at $18.41 on Nov 20, down 5.64% on the day. The next earnings report for NAMS is expected around Wed, Feb 3, 2027. For the quarter ended Sep 2026, NAMS reported EPS of -$0.14 on revenue of $19.2M, with revenue up 5406.9% from a year ago. Over its last 8 reports the stock moved an average of 5.4% the session after earnings. Over the last 12 months NAMS insiders bought $227K of stock on the open market and sold $63.3M, according to SEC Form 4 filings.

AI Auto Pilots
Is NAMS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold NAMS.

Key Stats

Last 12 months
Results
Revenue
$25.9M
−26.4% vs a year ago
Net income
−$204.9M
−789.9% margin
EPS (diluted)
−$1.69
Free cash flow
−$150.9M
−581.6% margin
Valuation
Market cap
$2.2B
119.9M shares
P/E
–
No P/E while losing money
Price to sales
85.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$423.1M
At Sep 30
Shareholder equity
$630.8M
Shares outstanding
119.9M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $102.7M$102.7MFY2022FY2023: $14.1M$14.1MFY2023FY2024: $45.6M$45.6MFY2024FY2025: $22.5M$22.5MFY2025

From NAMS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Feb 3
Estimated date · Time not announced
Reported EPS
-$0.14
Quarter ended Sep 2026
Year ago EPS
-$0.61
Same quarter last year
Revenue
$19.2M
+5406.9% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.95Dec '24Mar 2025: -$0.34Mar '25Jun 2025: -$0.15Jun '25Sep 2025: -$0.61Sep '25Dec 2025: -$0.63Dec '25Mar 2026: -$0.40Mar '26Jun 2026: -$0.52Jun '26Sep 2026: -$0.14Sep '26Latest -$0.14
Revenue by quarter
Dec 2024: $12.8MDec '24Mar 2025: $3.0MMar '25Jun 2025: $19.1MJun '25Sep 2025: $348,000Sep '25Dec 2025: $32,000Dec '25Mar 2026: $3.0MMar '26Jun 2026: $3.7MJun '26Sep 2026: $19.2MSep '26Latest $19.2M
How NAMS moved after its last 8 reports
Average move the session after a report ±5.4%
Aug 5, 2026Time not announced−0.5%
May 7, 2026Time not announced+12.5%
Feb 18, 2026Time not announced+1.5%
Jan 9, 2026Time not announced−4.0%
Nov 5, 2025Time not announced+4.4%
Aug 6, 2025Time not announced+8.7%
May 8, 2025Time not announced+1.9%
Feb 26, 2025Time not announced+10.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on NAMSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on NAMS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on NAMS

Technical Analysis

NAMS · as of the Nov 20 close · updated each morning
Downtrend

The stock is 7% below its 20 day and 15% below its 50 day average. It is 57% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 38). The nearest support is the 52 week low at $17.90, and the nearest resistance the Pivot at $18.82.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 7.0%/day
Key levels
$42.2052 week high+129.2%
$28.84200 day average+56.7%
$24.94100 day average+35.5%
$21.0950 day average+14.6%
$20.82Swing high (Nov 11)+13.1%
$19.7820 day average+7.4%
$19.36Pivot R1+5.2%
$18.82Pivot+2.2%
$18.41Last close
$17.9052 week low−2.8%
$17.90Swing low (Nov 9)−2.8%
$17.87Pivot S1−2.9%
Indicators
RSI (14)38.44Weak, oversold below 30Neutral
MACD-0.58Above its signal lineBullish
Stochastic30.3Middle of its rangeNeutral
ADX (14)13.4No clear trend
Williams %R-88.3Oversold below −80, overbought above −20Oversold
CCI (20)-141.6Oversold below −100, overbought above 100Oversold
Rate of change−2.6%Change over 10 sessionsBearish
ATR (14)$1.29Typical daily range, 7.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NAMS

What happened before

See how NAMS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow NAMS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How NAMS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for NAMSHow many large options trades hit NAMS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

NAMS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲107 buying vs 83 selling
  • ▲Held by funds +6.4 pts
  • ▼Funds holding -12
  • ▼Superinvestors: 2 added, 3 cut
  • ▲Put/call 14.81 to 1.79
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding183195−6.2%
In funds' top 1056−16.7%
Held by funds108.1%101.7%+6.4 pts
New / increased24 / 8345 / 70−7.0%
Reduced / sold out47 / 3650 / 20+18.6%
Put/call ratio1.7914.81−87.9%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NAMS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

NAMS Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$227K1 buy · 1 insider
Sold$63.3M19 sales · 6 insiders
71% of the selling was under pre-arranged trading plans.
2025-12 sold $5.2M2026-01 sold $8.5M2026-02 sold $12.2M2026-03 sold $26.0M2026-05 sold $2.3M2026-06 sold $1.2M2026-07 sold $3.2M2026-08 sold $3.4M2026-09 bought $227K2026-09 sold $1.3MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 30Johannes Jacob Pieter KasteleinChief Scientific OfficerSale plan50,246$25.03$1.3M
Sep 14Michael H. DavidsonCEOBuy10,000$22.65$227K
Sep 4John W SmitherDirectorSale1,600$25.32$41K
Aug 24Johannes Jacob Pieter KasteleinChief Scientific OfficerSale plan125,000$26.91$3.4M
Jul 20Louise Frederika KooijChief Accounting OfficerSale plan105,000$30.34$3.2M
Jun 22Louise Frederika KooijChief Accounting OfficerSale plan40,000$30.20$1.2M
Every insider buy and sale for NAMS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See NAMS insider trades →

From SEC Form 4 filings by NAMS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NAMS is in one of them and how their past NAMS trades turned out.

NAMS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NAMS in an article yet. Here's the latest on the wider market.

About NewAmsterdam Pharma Co N.V.

NewAmsterdam Pharma is a biopharmaceutical company based in Naarden, Netherlands. It is developing obicetrapib, a once-a-day oral pill for lowering LDL cholesterol in patients with cardiovascular disease or high cholesterol who do not reach their targets on statins alone. The drug can be taken on its own or combined with ezetimibe, another cholesterol-lowering pill. The company plans to sell it in the United States itself and has given Menarini the rights to market it in most of Europe.

Headquarters
Narrden, Netherlands